ImmuCell appointed Kathy Turner to its board, effective April 1, 2026. She replaces Steven Rosgen, who is retiring from the board after serving since January 2018. Turner will chair the Compensation and Stock Option Committee and join the Audit Committee. She previously held senior leadership roles at IDEXX from 2014 to 2023, including Chief Marketing Officer and Senior Vice President of International Operations. Turner also previously served on the board of Elanco and spent nearly 30 years at Abbott in global commercial operations roles.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603181605PRIMZONEFULLFEED9674708) on March 18, 2026, and is solely responsible for the information contained therein.